最后更新: 8 月 15, 2026
A large part of my clinic is men who arrived with one number on a health-check report: a PSA above the 4.0 ng/mL cutoff. They are frequently very frightened by the time they sit down, and much of the consultation is spent explaining what that number does and does not mean. So let me start where I start with them.
An elevated PSA usually does not mean cancer. It means the prostate has leaked more of one particular enzyme into the blood than expected — and there are several ordinary reasons for that.
What PSA actually is
PSA stands for Prostate Specific Antigen, an enzyme made only by the prostate, whose job is to liquefy semen after ejaculation. It sits at high concentration inside prostate tissue and at very low concentration in the bloodstream. Anything that disturbs prostate tissue — an enlarged prostate, infection, or even minor manipulation of the gland — lets PSA leak into the blood and pushes the number up. When that happens without cancer being present, we call it a false positive.
Note what the name does 不 say: PSA is prostate-specific, not cancer-specific. That single distinction explains most of what follows.

Why screening everyone is no longer recommended
In 2018 a landmark US review concluded that universal PSA screening is not right for everyone: a modest benefit in men aged 55–69, and no benefit in men aged 70 and above. The reasoning is worth understanding rather than just accepting.
- The point of screening is to find high-risk localised prostate cancer, early enough to treat it successfully.
- Much prostate cancer is indolent — slow enough never to cause trouble. Autopsy studies found that about 33% of men who died of something else had prostate cancer nobody had detected, and it had not harmed them.
- Roughly 1 in 1,000 men screened genuinely benefits.
- False positives lead to biopsies that were not needed — with pain, blood in the urine or semen, and infection — and sometimes to treatment of a harmless cancer, which carries its own risks of erectile dysfunction and urinary incontinence.
Put plainly: screening can save a life, and it can also cause harm to a man who was never going to be harmed by his cancer. That is the trade-off, and it is why the recommendation is a conversation rather than a rule.

Who should start the conversation earlier
The 55–69 window applies to men at average risk. Some men are not at average risk and should raise it sooner, at around 40–45:
- A father or brother who has had prostate cancer
- Men of African descent, in whom prostate cancer occurs earlier and more aggressively
- A known family history of certain inherited cancer syndromes, which is worth mentioning to your doctor
One thing that has changed since 2018
Much of the harm in the list above comes from the assumption that a raised PSA leads more or less automatically to a needle biopsy. That is no longer the case. MRI of the prostate before biopsy can distinguish suspicious areas from an innocent gland, and spares a substantial proportion of men a biopsy they did not need. Where a biopsy is still required, the MRI-fusion transperineal technique targets the suspicious area rather than sampling blindly.
This matters for your decision: the balance of benefit and harm in a 2018 review reflected the pathway as it was then, and the harm side of that equation is smaller now than it was.
So what should you do?
If you are a man aged 55–69, discuss PSA screening with your doctor and reach a decision together, in the light of your own risk and your own view of the trade-off. It is genuinely your choice — there is no single right answer that applies to every man, which is exactly why the guidance stops short of telling you what to do.
And if you have already had a high result, do not panic before you have the full picture: here is what a high PSA actually means and what happens next. Screening is also only worth doing if effective treatment follows a positive result — you can read what that treatment involves on the prostate cancer surgery service page.
如果您对PSA筛查有疑问,或PSA检测结果升高,Soarawee Weerasopone医生将在曼谷医院总部提供专家咨询。. 预约咨询. 如需预约三美泰是拉差医院,请致电泌尿科: 088-022-1445.
PSA筛查常见问题
PSA (Prostate Specific Antigen) is a blood test that measures the level of an enzyme produced by the prostate gland. Elevated PSA may indicate prostate cancer, but it can also be raised by benign conditions such as BPH, prostatitis, or even minor prostatic manipulation. PSA is prostate-specific, not cancer-specific. It is used as a screening tool for prostate cancer, particularly in men aged 55–69, but must be interpreted carefully in context with other clinical information.
目前没有证据支持普适性的PSA筛查。2018年一项具有里程碑意义的美国研究发现,PSA筛查仅在中老年男性(55-69岁)中显示出适度益处,而在70岁及以上男性中则未发现任何益处。常规筛查可能导致假阳性结果,引起不必要的焦虑和前列腺活检。是否进行筛查的决定应通过患者和医生共同协商,个体化决定。.
前列腺特异性抗原 (PSA) 水平升高并不一定意味着患有前列腺癌。PSA 水平升高的常见非癌性原因包括良性前列腺增生 (BPH)、急性前列腺炎、尿路感染以及近期对前列腺的刺激。泌尿科医生会在评估 PSA 水平的同时,结合患者年龄、前列腺体积、PSA 随时间的变化趋势以及临床检查结果,然后才会建议进行前列腺活检。许多 PSA 水平升高的男性并没有患前列腺癌。.
The main risks of PSA screening stem from false positive results. A falsely elevated PSA may lead to a prostate biopsy, which carries risks including pain, hematuria (blood in urine), hematospermia (blood in semen), and infection. If biopsy leads to unnecessary treatment for indolent (non-harmful) cancer, additional risks include erectile dysfunction and urinary incontinence from surgery or radiation. Pre-biopsy MRI now spares many men a biopsy they would previously have undergone, which reduces this harm.
Current evidence supports considering PSA screening in men aged 55–69 after an informed discussion with a doctor about the potential benefits and harms. Men with higher risk – such as those with a first-degree relative with prostate cancer or men of African descent – may benefit from starting discussions earlier, around age 40–45. Men aged 70 and above generally do not benefit from PSA screening according to current guidelines.
免责声明 本文由曼谷医院总院的董事会认证泌尿科医师索拉维·维拉索蓬(Soarawee Weerasopone)博士撰写并审核。本内容仅供教育目的,不构成医疗建议。通过私人消息渠道不提供任何医疗建议、诊断或处方。在开始任何医疗治疗之前,请务必咨询合格的医疗保健专业人员。.
医学撰写与审阅: Soarawee Weerasopone 博士(Pom 博士)——曼谷医院总部泌尿外科专科医生,自 2016 年起从事泌尿外科工作。曾于 2019 年在台湾长庚纪念医院接受机器人手术培训;2022 年在东京顺天堂大学医院接受泌尿外科内镜观察培训;2025 年至 2026 年在美国贝勒医学院斯科特泌尿外科系担任研究学者和临床观察员。.

素拉威·韦拉索蓬医生(Dr. Pom)是曼谷总医院总部(Bangkok Hospital Headquarters)的特许泌尿外科医师,专长于男性健康、机器人手术(达芬奇 Xi 系统)以及肾结石治疗。他目前是贝勒医学院(Baylor College of Medicine)斯科特泌尿外科系(在莫希特·克拉教授 Mohit Khera 指导下)的研究学者和临床观察员(2025–2026年)。他曾于2019年在台湾长庚纪念医院完成机器人手术专科培训,并于2022年在东京顺天堂大学附属医院完成泌尿内腔镜观察学习。.


4 回复